Skip to content
DataLookout
Menu

NCT03326921

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

StatusSuspended
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 38 versions: 31 with changes below, 7 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Stopped Recruitment suspended Sponsor's reason: On recruitment pause for administrative reason (funding) Show 4 more changesShow less
    • Eligibility criteria expanded, about 19 words
    • Secondary endpoints: details revised at 5 of 9 entries
    • Site details revised
    • Publications: details revised at 1 of 1 entry
  2. Notable Eligibility criteria shortened, about 6 words
    • Interventions: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR (Biological), Laboratory Biomarker Analysis (Other) to Biospecimen Collection (Procedure), Bone Marrow Aspiration (Procedure), CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR…
    • Secondary endpoints revised (9)
    v36
  3. Notable Trial status: Suspended to Recruiting
    • Study description expanded, about 12 words
    • Site details revised
    v35
  4. Minor Interventions: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR (Biological), Fludarabine (Drug), Laboratory Biomarker Analysis (Other) to CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR (Biological), Laboratory Biomarker Analysis (Other)
    • Study description expanded, about 18 words
    • Collaborators: 1 to 2
    v34
  5. Stopped Trial status: Recruiting to Suspended Sponsor's reason: Pause in funding
    • Site details revised
    v33
Show 25 earlier versionsHide 25 earlier versions
  1. Notable Trial status: Suspended to Recruiting
    • Site details revised
    v32
  2. Notable Primary completion date: Oct 16, 2024 to Oct 16, 2027
    • Study completion date: Jul 16, 2025 to Jul 16, 2028
    v29
  3. Notable Eligibility criteria shortened, about 58 wordsv27
  4. Stopped Trial status: Recruiting to Suspended Sponsor's reason: Pause in funding
    • Site details revised
    v26
  5. Minor Collaborators: 4 to 1v24
  6. Minor Site contact updatedv22
  7. Notable Eligibility criteria expanded, about 58 wordsv21
  8. Notable Eligibility criteria expanded, about 5 words
    • Study description shortened, about 151 words
    v20
  9. Notable Primary completion date: Dec 16, 2023 to Oct 16, 2024
    • Study completion date: Oct 16, 2024 to Jul 16, 2025
    v19
  10. Notable Eligibility criteria shortened, about 56 words
    • Study description revised
    v18
  11. Minor Collaborators: 3 to 4
    • Study title revised
    • Study description shortened, about 1 word
    v17
  12. Notable Trial status: Suspended to Recruiting
    • Site details revised
    v16
  13. Stopped Trial status: Recruiting to Suspended Sponsor's reason: COVID19 Suspension
    • Site details revised
    v15
  14. Notable Trial status: Suspended to Recruiting
    • Site details revised
    v14
  15. Stopped Trial status: Recruiting to Suspended Sponsor's reason: COVID19 Suspension
    • Site details revised
    v13
  16. Notable Primary completion date: Dec 16, 2019 to Dec 16, 2023
    • Study completion date: Oct 16, 2020 to Oct 16, 2024
    v11
  17. Notable Eligibility criteria expanded, about 18 words
    • Interventions: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR (Biological), Fludarabine Phosphate (Drug), Laboratory Biomarker Analysis… to CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR (Biological), Fludarabine (Drug), Laboratory Biomarker Analysis (Other)
    v10
  18. Minor Site contact updatedv9
  19. Notable Eligibility criteria expanded, about 9 words
    • Study description shortened, about 1 word
    v8
  20. Notable Start date: Dec 14, 2017 to Feb 23, 2018
    • Eligibility criteria shortened, about 322 words
    • Secondary endpoints: details revised at 2 of 9 entries
    • Study description revised
    v7
  21. Minor Start date changed from estimate of Jun 23, 2018 to Dec 14, 2017v6
  22. Notable Start date: Apr 23, 2018 to Jun 23, 2018v5
  23. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Mar 1, 2018 to Apr 23, 2018
    • Secondary endpoints: details revised at 1 of 9 entries
    • Site details revised
    v4
  24. Notable Start date: Jan 1, 2018 to Mar 1, 2018v3 Show 5 more changesShow less
    • Eligibility criteria expanded, about 61 words
    • Interventions: Fludarabine Phosphate (Drug), Immunotherapy (Biological), Laboratory Biomarker Analysis (Other) to CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR (Biological), Fludarabine Phosphate (Drug), Laboratory Biomarker Analysis…
    • Secondary endpoints revised (9)
    • Study description revised
    • Collaborators reordered
  25. Notable Start date: Nov 1, 2017 to Jan 1, 2018v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Feasibility of manufacturing minor H antigen (HA-1) T cell receptor (TCR) CD8+ and CD4+ T cells
Timeframe: At time of T cell infusion (at day 0)
Feasibility of administering minor H antigen (HA-1) T cell receptor (TCR) CD8+ and CD4+ T cells
Timeframe: At time of T cell infusion (at day 0)
Incidence of dose-limiting toxicities of HA-1 T cell receptor (TCR) T cells
Timeframe: Up to 12 weeks after T-cell infusion

Secondary (9)

Duration of in vivo persistence of transferred HA-1 T cell receptor (TCR) CD4+ T cells in peripheral blood
Duration of in vivo persistence of transferred HA-1 T cell receptor (TCR) CD8+ T cells in peripheral blood
Presence, proportion and persistence of HA-1 T cell receptor (TCR) CD4+ T cells in the bone marrow
Presence, proportion and persistence of HA-1 T cell receptor (TCR) CD8+ T cells in the bone marrow
Specific cytolytic activity of HA-1 T cell receptor (TCR) CD8+ and CD4+ T cells against HLA-A*0201+ HA-1+ target cells before adoptive T cell transfer
Show 4 moreShow less
Specific cytolytic activity of HA-1 T cell receptor (TCR) CD8+ and CD4+ T cells against HLA-A*0201+ HA-1+ target cells after adoptive T cell transfer
Reduction of leukemia in the bone marrow in subjects who have measurable leukemia in the marrow prior to HA-1 T cell receptor (TCR) T cell infusion
Reduction of recipient normal hematopoietic cells in the bone marrow in subjects who have measurable recipient normal hematopoietic cells in the marrow prior to HA-1 T cell receptor (TCR) T cell infusion
Proportion of subjects who develop new or recurrent symptoms or signs of graft-versus-host disease

Arms and interventions

Treatment (CD4+ and CD8+ HA-1 TCR T cells)Experimental

Patients receive lymphodepleting chemotherapy (e.g., fludarabine and cyclophosphamide or debulking regimens as specified in the protocol) ending 2-14 days prior to HA-1 TCR T cell administration. Patients then receive CD4+ and CD8+ HA-1 TCR T cells IV.

Biologicals: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR

Procedures: Bone Marrow Aspiration, Biospecimen Collection

Sites

1 site in 1 country

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States